Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT05619367
NCT05619367AvailableNot Applicable

A Compassionate Use (CU) Program of Odronextamab

Regeneron Pharmaceuticals0 sitesStarted: November 16, 2022Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Available
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Provide compassionate use of odronextamab

Study Design

Study Type
Expanded Access

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Similar Trials

Approved For Marketing
Not Applicable
Omegaven for Compassionate Use in the Treatment of Parenteral Nutrition-Associated Liver DiseaseCholestasisLiver Diseases
NCT03072667Catherine Cibulskis, MD
Available
Not Applicable
Fremanezumab Managed Access Program for Pediatric PatientsMigraine
NCT03539393Teva Branded Pharmaceutical Products R&D LLC
No Longer Available
Not Applicable
Compassionate Use Program With Brivaracetam for the Treatment of Patients With EpilepsyEpilepsy
NCT03532516UCB Biopharma SRL
Completed
Phase 3
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's SyndromeCushing's DiseaseCushing's Syndrome
NCT01371565Corcept Therapeutics4
Approved For Marketing
Not Applicable
Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical TrialDiabetic Peripheral Neuropathic PainMajor Depressive DisorderFibromyalgiaGeneralized Anxiety Disorder
NCT00071708Eli Lilly and Company